Want to see BMEA full AI Analyst Report?
BMEA Stock Chart & Stats
$2.21
$0.07(1.75%)
At close: 4:00 PM EST
$2.21
$0.07(1.75%)
Day’s Range― - ―
52-Week Range$0.87 - $2.99
Previous CloseN/A
Volume309.16K
Average Volume (3M)2.40M
Market Cap
$93.27M
Enterprise Value$66.80
Total Cash (Recent Filing)$44.69M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 03, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding72,299,440
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.20Price Target Upside225.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Discovery PlatformA proprietary covalent drug discovery platform is a durable competitive asset: it can generate multiple internally discovered candidates, accelerate targeted chemistry, and create differentiation versus standard modalities. Platform-driven pipelines increase optionality and long-term upside across oncology and metabolic indications.
Positive Phase 2 T1D DataRobust 52-week Phase 2 data demonstrating durable preservation of beta cell function provides structural clinical de-risking. The result validates a non-immunosuppressive biology, supports follow-on Phase 2 plans in H2 2026, and meaningfully improves the program's probability of advancing toward registration or partnership.
Low Financial LeverageModest debt levels reduce solvency and interest-rate risk for a cash-burning clinical-stage biotech. Low leverage preserves strategic flexibility to raise non-debt capital, pursue collaborations, or extend programs without immediate refinancing pressure, a structurally positive factor for 2-6 month planning horizons.
Bears Say
No Product RevenueZero product revenue is a persistent structural constraint: the company must rely on external financing, collaborators, or milestone deals to fund operations. Over the medium term this increases dilution and limits self-funding options for advancing multiple programs simultaneously.
Ongoing Cash BurnContinued negative operating and free cash flow, even with improvement versus prior year, implies recurring funding needs. Free cash flow tracking net losses (~1.0) means accounting losses translate to real cash outflows, compressing runway and forcing financing or partnership decisions within months.
Eroding Equity BaseSharp decline in equity and assets weakens the balance-sheet buffer against future losses and raises funding risk. A depleted capital base constrains strategic optionality, increases probability of dilutive financing under adverse conditions, and limits ability to absorb clinical or development setbacks.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.87 and its highest was $2.99 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $93.27M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Aug 03, 2026 which is in 10 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on May 06, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.231 by $0.061.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.22.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 72,299,440 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.231. Following the earnings report the stock price went up 1.875%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biomea Fusion Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (225.79% Upside)
$7.20 (225.79% Upside)
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.75%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
BMEA Stock 12 Month Forecast
Average Price Target
$7.20
▲(225.79% Upside)
Technical Analysis
Ownership Overview
8.66% Insiders
11.22% Mutual Funds
1.17% Other Institutional Investors
74.82% Public Companies and
Individual Investors